Thad Huston will join LivaNova PLC as its new Chief Financial Officer

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

“I am eager to join the exceptional team at LivaNova,” said Huston. “We share a passion for making a difference in patients’ lives, while focusing on growth that will lead us to even greater success as a company.”

LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, announced Thad Huston will join the Company as its new Chief Financial Officer (CFO), effective May 20, 2017. LivaNova’s former CFO, Vivid Sehgal, is coordinating with Huston to ensure an orderly transition. Huston will report directly to Damien McDonald, Chief Executive Officer (CEO).

Huston is a highly strategic global finance executive who joins LivaNova after more than 25 years at Johnson & Johnson (J&J), having most recently served as Group Chief Financial Officer, Medical Devices. While at J&J, Huston was pivotal in accelerating the growth for many of its divisions through focused strategies, calculated investments in innovation and streamlined productivity.

“I am pleased to welcome Thad Huston to LivaNova and to our Executive Leadership Team as our new CFO,” said Damien McDonald, LivaNova CEO. “Thad is equipped with a strong healthcare and medical device background, coupled with the financial acumen and acuity to enhance our strategic growth plans. I look forward to working together to drive performance, build our pipeline and expand our portfolio in a sustainable manner.”

During his tenure at J&J, Huston held various senior roles, including: President of J&J’s Xian-Janssen Pharmaceuticals division in China; Vice President – Finance, Chief Financial Officer and Chief Operations Officer in J&J Pharmaceutical Research and Development; as well as Vice President – Finance and Chief Financial Officer at Ortho-McNeil Pharmaceuticals. Prior to this, he held senior financial roles at various J&J locations in the U.S., China, Belgium, Russia and Hungary.

“I am eager to join the exceptional team at LivaNova,” said Huston. “We share a passion for making a difference in patients’ lives, while focusing on growth that will lead us to even greater success as a company.”

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.